News from neurosigma, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jan 06, 2015, 07:00 ET

FDA Grants NeuroSigma Humanitarian Use Device (HUD) Designation

NeuroSigma®, Inc. (NeuroSigma) today announced that it has received a Humanitarian Use Device (HUD) designation from the Food and Drug...

Jan 05, 2015, 07:00 ET

UCLA Launches Phase II Pediatric Clinical Trial for the Treatment of ADHD with NeuroSigma's eTNS System

 NeuroSigma®, Inc. (NeuroSigma) today announced that enrollment has commenced for a 90-subject Phase II pediatric clinical trial of its...

Nov 19, 2014, 07:00 ET

NeuroSigma Congratulates Brazilian Medical Team for Their Top-Line Results in Phase II Clinical Trial of eTNS for Treatment of Depression

 NeuroSigma®, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive external...

Nov 17, 2014, 07:00 ET

NeuroSigma Announces Top-Line Findings of UCLA Phase II Clinical Trial of eTNS for the Treatment of Depression

 NeuroSigma®, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS...

Nov 03, 2014, 07:00 ET

NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS)

 NeuroSigma®, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS...

Oct 21, 2014, 07:00 ET

NeuroSigma Receives Notice of Allowance of U.S. Patent Application

LOS ANGELES, Oct. 21, 2014 /PRNewswire/ – NeuroSigma®, Inc. (NeuroSigma), a California-based life sciences company focused on...

Oct 15, 2014, 07:00 ET

NeuroSigma and the U.S. Veterans Administration (VA) Enter into Cooperative Research and Development Agreement (CRADA)

 NeuroSigma®, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS...

Aug 26, 2014, 18:45 ET

NeuroSigma, Inc. Files Registration Statement for Proposed Initial Public Offering

 NeuroSigma, Inc., a Los Angeles-based life sciences company established to develop bioelectronic technologies, today announced that it has...

Aug 25, 2014, 07:00 ET

U.S. Army Funds Phase II Clinical Trial at UCLA for the Treatment of PTSD with the NeuroSigma eTNS System

NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™ eTNS™...

Jul 22, 2014, 07:00 ET

Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome

 NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™...

Jul 09, 2014, 07:00 ET

NIH Funds Phase 2 Clinical Trial at UCLA for the Treatment of ADHD with NeuroSigma's eTNS System

 NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™...

Jul 08, 2014, 07:00 ET

Advances in Trigeminal Nerve Stimulation Featured at European Congress on Epileptology in Stockholm, Sweden

 NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™...

Jun 03, 2014, 07:00 ET

Leading UCLA Physician Dr. Ian Cook Joins NeuroSigma As Chief Medical Officer and Senior Vice President

 NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™...

Apr 01, 2014, 07:00 ET

NeuroSigma Receives Approval from Australian Therapeutic Goods Administration to Market its Monarch™ eTNS™ System for the Adjunctive Treatment of Drug-Resistant Epilepsy

 NeuroSigma, Inc., a California-based life-sciences company focused on commercialization of its non-invasive Monarch™ eTNS™ System...

Mar 28, 2014, 07:00 ET

NeuroSigma Expands Its Management Team with Two Former Amgen Finance Executives

 NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™...

Feb 25, 2014, 07:00 ET

David Hayes, Former Partner at O'Melveny & Myers LLP and Haynes and Boone LLP, Joins NeuroSigma As Chief Administrative Officer, General Counsel and Sr. Vice President

 NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™...

Feb 11, 2014, 06:00 ET

Former Amgen Finance Executive Carl Adams Joins NeuroSigma As Vice President and Controller

 NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™...

Jan 27, 2014, 06:00 ET

Former Allergan Marketing Executive Gregory F. Brooks Joins NeuroSigma As Senior VP and Chief Commercial Officer

NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™ eTNS™...

Jan 21, 2014, 05:00 ET

External Trigeminal Nerve Stimulation (eTNS) Presentations at the American Epilepsy Society Meeting

 NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company, today announced that two presentations were made last month at the...

Dec 05, 2013, 07:00 ET

NeuroSigma Announces Receipt of Notice of Allowance of U.S. Patent Application Related to External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Epilepsy and other Neurological Disorders

 NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company, announced today that the U.S. Patent and Trademark Office...